SCHEMBL5118325

SCHEMBL5118325

O=C(NCCc1cccc(Oc2ccnc(C3=NCCN3)c2)c1)c1cccc(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
GRM5 P41594 1/20 0.45
PARP1 P09874 3/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
KDM5B Q9UGL1 2/20 0.43
KDM4E B2RXH2 1/20 0.43
KDM5A P29375 1/20 0.43
KDM5C P41229 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
HDAC2 Q92769 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107435 0.89 RAB9A (0.51) RAB9ANPC1PARP1LMNAKDM5B
SCHEMBL4117437 0.89 NPC1 (0.48) RAB9ANPC1GRM5PARP1HRH3
SCHEMBL4094674 0.88 WDR5 (0.46) RAB9ANPC1GRM5KDM5BKDM4E
SCHEMBL4099502 0.88 GAA (0.51) RAB9AGRM5KDM5BKDM4EKDM5A
SCHEMBL14266530 0.88 RAB9A (0.44) RAB9ANPC1KDM5BKDM4EKDM5A
SCHEMBL4118391 0.87 TRPV1 (0.46) RAB9AKDM5BKDM4EKDM5AKDM5C
SCHEMBL4106626 0.87 KDM5B (0.43) RAB9ANPC1PARP1KDM5BKDM4E
SCHEMBL14266570 0.87 CDK8 (0.49) PARP1HRH3KDM5BKDM4EKDM5A
SCHEMBL4105629 0.84 CDK8 (0.41) RAB9AKDM5BKDM4EKDM5AKDM5C
SCHEMBL4100756 0.83 CDK8 (0.51) KDM4EHDAC2HDAC8HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MAP4K5, MAP3K5, MAP4K2 RAB9A 1730/4885NPC1 3081/4885GRM5 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.